Form 4 Filing for KalVista Pharmaceuticals, Inc.

This filing details transactions made by Brian Piekos, Chief Financial Officer of KalVista Pharmaceuticals, Inc. On April 16, 2026, Piekos acquired 6,250 shares of Common Stock through the settlement of Restricted Stock Units (RSUs) with a reported price of $0.00. This transaction resulted in a post-transaction share count of 20,012. Additionally, on the same date, 6,250 RSUs were acquired, with each RSU representing a contingent right to one share of Common Stock. On April 17, 2026, Piekos sold 1,862 shares of Common Stock at a price of $20.2163 per share. This sale was to cover tax withholding obligations related to the vesting and settlement of RSUs, as indicated by footnote F2, and does not represent a discretionary transaction. Following this sale, Piekos holds 18,150 shares of Common Stock. The RSUs vest quarterly starting April 16, 2026, with 1/16th of the total shares vesting each quarter, contingent upon continued service.